Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 00)
Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 68462-733
12 FDA label images from Glenmark Pharmaceuticals Inc., Usa · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 68462-733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Cid:[email protected] (6d85f252 307c 4aa8 9572 1e74c9819283 01)
Blister
A weekly calendar-style dosing chart for Drospirenone and Ethinyl Estradiol Tablets, USP 3 mg/0.03 mg. The chart is organized in a 4-week grid with days of the week labeled horizontally from Sunday to Saturday and weeks labeled vertically from Week 1 to Week 4. Circular checkboxes are provided for each day, with arrows indicating the order of daily use starting from Sunday week 1.*
Carton (Carton)
Packaging label for drospirenone and ethinyl estradiol tablets, USP, 3 mg/0.03 mg, in a kit dosage form. The label indicates the product contains 3 blisters, each with 28 tablets. The product is labeled and manufactured by Glenmark Pharmaceuticals Inc., USA. The label also includes storage instructions and pharmacist dispensing information.*
Figure 3
A forest plot illustrating effect estimates from multiple studies comparing contraceptive use. The chart separates studies into two groups: 'Ever COC vs. Never COC Use' and 'Current COC use vs. Never-Use.' Each study is listed by name and year, with horizontal lines and dots representing confidence intervals and point estimates. Numeric values for odds ratio (OR), relative risk (RR), and hazard ratio (HR) with their confidence intervals are shown.*
Figure1 (Figure1)
A forest plot chart showing hazard ratios, rate ratios, and odds ratios from multiple studies including Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD studies. The horizontal axis is logarithmic, ranging from 0.1 to 10 with a reference line at 1. Studies are grouped by prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases categories, each displaying point estimates with confidence intervals.*
Figure2 (Figure2)
A horizontal bar chart titled 'Likelihood of Developing a VTE' comparing four groups: Non-Pregnant Non-COC user, COC-User, Pregnancy, and Postpartum (12 weeks only). The chart shows the number of women with a blood clot per 10,000 women-years, with risk ranges: 1 to 5 for Non-Pregnant Non-COC users, 3 to 9 for COC-Users, 5 to 20 for Pregnancy, and 40 to 65 for Postpartum. A note explains pregnancy data assumptions based on reference studies.*
Drospirenone Structure (Image 03)
Chemical structure of drospirenone, showing its steroidal framework with ketone and lactone functional groups.*
Ethinyl Estradiol Structure (Image 04)
Chemical structure diagram of drospirenone and ethinyl estradiol showing molecular framework with labeled hydroxyl groups and double bonds.*
Img1 (Img1)
A diagram showing the relative effectiveness of various birth control methods, ranked from fewer pregnancies to more pregnancies per 100 women in one year. It categorizes methods like implants, injections, intrauterine devices, sterilization as most effective, followed by birth control pills, skin patches, vaginal rings, then condoms and diaphragms, then behavioral methods and withdrawal, with no birth control resulting in the most pregnancies.*
Img3 (Img3)
A horizontal bar chart comparing the number of women with a blood clot out of 10,000 women years (WY) across four groups: Non-pregnant non-COC users (1 to 5), COC users (3 to 9), pregnant women (5 to 20), and postpartum women within 12 weeks (40 to 65). The chart highlights the relative risk of blood clots for each group with clear ranges for each category.*
Pouch (Pouch)
Label for Drospirenone and Ethinyl Estradiol Tablets, USP 3 mg/0.03 mg kit containing 1 blister of 28 tablets. Label includes storage instructions, manufacturer information as Glenmark Pharmaceuticals Limited and Glenmark Pharmaceuticals Inc., USA, a barcode, and dosage directions. The label has a floral background with purple text and the Glenmark logo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
